NASDAQ · PSNL

Personalis, Inc.

$11.98 +$0.20 (+1.70%) 1D After hours

Key Metrics

$1.26B
Market cap
P/E · TTM
$64.52M
Revenue · TTM
−$95.55M
Net income
EPS · TTM $-1.09
Dividend yield
Free cash flow −$84.65M
Beta · 1Y 2.90
EBITDA · TTM −$85.69M
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 20
    A material event was filed (Form 8-K).

    8-K - Personalis, Inc. (0001527753) (Filer)

    RECEIPT: SEC FORM 8-K, TIMESTAMPED
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • May 28
    The stock moved +15.7% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, May 28
  • Apr 29
    From its Jan 29 high, the share price fell 49%.

    Peak close $9.97 on Jan 29; trough close $5.04 on Apr 29. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -49%
  • Mar 12
    The stock moved -17.1% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Mar 12

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$1.26B
Enterprise value
Shares outstanding106.8M
52-wk range$3.84 – $16.39
Avg volume · 20D881.9K
Net cash
Book value / share$2.91
IndustryServices-Medical Laboratories
ExchangeNASDAQ
About Personalis, Inc.
IPO dateJun 20, 2019
Employees260

Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S19.49
P/FCF
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross
Operating -148.1%
Net -148.1%
FCF -131.2%
ROE / ROIC -41.8% · -443.5%

Financial Health

Current ratio6.61
Quick ratio
Debt / equity
Debt / EBITDA
Net cash
Working capital$219.15M

Cash Flow · TTM

Operating CF −$79.46M
Capex −$5.19M
Free cash flow −$84.65M
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

3 / 9
Weak fundamentals · 3 of 9 signals passing

Altman Z-Score

7.9
Safe zone (> 2.99) · bankruptcy risk negligible

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings